AbbVie and Teneobio have partnered to develop and commercialise TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.
B-cell maturation antigen (BCMA) has emerged as an attractive target for multiple myeloma therapeutics. TNB-383B is a bispecific antibody that simultaneously targets BCMA and CD3, utilising Teneobio’s unique anti-CD3 platform.
Through this dual targeting mechanism, TNB-383B is designed to direct the body’s own immune system to target and kill BCMA expressing tumour cells.
Teneobio said it expects to begin the clinical program for TNB-383B in the first half of 2019.
“Combined with AbbVie’s commitment to scientific advancement and bringing oncology products to the world-wide commercial market, we will be able to quickly progress the development of TNB-383B for patients in need,” said Roland Buelow, CEO of Teneobio and its affiliate TeneoOne.
“Developing novel targeted treatments for patients with cancer continues to be our key priority,” said Mohit Trikha, vice president and head, oncology early development, AbbVie.
“Multiple myeloma is one of the most common haematological cancers and an area of significant medical need.
“Teneobio’s novel approach to T-cell redirection with TNB-383B has the potential to be a treatment option that may offer new hope for myeloma patients.”
The agreement will see TeneoOne receive an upfront payment of $90 million. The company will also continue developing TNB-383B through Phase 1.
AbbVie will hold the exclusive right to acquire TeneoOne and lead subsequent global development and commercialisation of TNB-383B.
If AbbVie exercises its right to acquire TeneoOne, the former stockholders of TeneoOne will also be eligible for regulatory and commercial sales milestones.